Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canlet.2012.02.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Maternal Phthalate Exposure Alters Prostate Proteome in Rat Offspring: Linking Omics Insights to Prostate Cancer Risk in Humans.
Arch Med Res
September 2025
Department of Structural and Functional Biology, Institute of Biosciences, São Paulo State University, Botucatu, SP, Brazil. Electronic address:
Background: Phthalates are compounds used as plasticizers to increase the flexibility of plastics and are considered endocrine disruptors. Some studies suggest that the origin of prostate cancer (PCa) may be associated with disturbances during embryo-fetal development. Previous data showed that perinatal exposure to the same phthalate mixture (PM) used here increased the incidence of adenocarcinomas in the prostates of aged rats.
View Article and Find Full Text PDFASO Visual Abstract: The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes after Radical Cystectomy and Ileal Conduit Urinary Diversion.
Ann Surg Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
Cancer-specific mortality in secondary bladder cancer after nephroureterectomy for upper tract urothelial carcinoma.
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Objective: To examine differences in cancer-specific mortality (CSM) in nonmetastatic upper tract urothelial carcinoma (UTUC) patients with vs. without secondary bladder cancer (BCa) after radical nephroureterectomy (RNU).
Methods: Within the Surveillance, Epidemiology, and End Results database (SEER 2000-2021), T1-T4N0M0 UTUC patients treated with RNU and diagnosed with secondary BCa were identified.
Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort.
Eur Urol Oncol
September 2025
The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Background And Objective: The effect of family history (FH) on prostate cancer active surveillance outcomes is unknown. Our objective is to evaluate FH of prostate, breast, ovarian, and/or pancreatic cancer in a large prospective active surveillance cohort.
Methods: Patients with recorded FH data (N = 1421) were selected.
Prophylactic Pelvic Nodal Radiation Therapy in High-risk Node-negative Prostate Cancer: The Case Against.
Int J Radiat Oncol Biol Phys
October 2025
Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.